Fiala

Peptide library › Metabolic & weight

Pemvidutide

In clinical trialsMetabolic & weight

Experimental weekly injection that acts on GLP-1 and glucagon receptors, studied for obesity and fatty liver disease.

What people use it for

What Pemvidutide does in the body

A dual agonist: the GLP-1 part reduces appetite, while the glucagon part increases energy use and fat burning in the liver. The aim is weight loss with a strong effect on liver fat and better preservation of muscle.

Strength of evidence

Moderate: Phase 2 trials showed meaningful weight loss and large drops in liver fat.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

Investigational. Not approved by the FDA or any regulator.

How it's taken

Route: Injection under the skin, once weekly (in trials)

How long it lasts (half-life): Long-acting; designed for weekly dosing

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Pemvidutide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Pemvidutide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Metabolic & weight